Skip to main content
. 2021 Aug 27;32:102796. doi: 10.1016/j.nicl.2021.102796

Table 1.

Demographics of Study Sample.

Demographics
N 20
Age (mean (SD)) 45.5 (12.4)
Male (%) 8 (40)
Phenotype (%)
 Primary progressive MS 3 (15)
 Relapsing-remitting MS 12 (60)
 Secondary progressive MS 5 (25)
Disease Duration (mean (SD)) 15.1 (9.0)
EDSS (median (range)) 2.5 (1.0–7.0)
Treatments (%)
 Untreated 6 (30)
 Glatiramer acetate 1 (5)
 Interferon beta-1a 4 (20)
 Dimethyl fumarate 6 (30)
 Fingolimod 1 (5)
 Natalizumab 1 (5)
 Rituximab 1 (5)